Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

J. Afonso, S. Lopes, R. Gonçalves, P. Caldeira, P. Lago, H. Sousa, J. Ramos, A. Gonçalves, P. Ministro, I. Rosa, A. Vieira, C. Dias, F. Magro • 10/1/2016

Abstract

Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA‐based, with a turnaround time of approximately 8 h, and delaying the target dosage adjustment to the following infusion.

Citations: 56